Acquired angioedema (AAE)

Acquired Angioedema (AAE): A Comprehensive Overview

Acquired Angioedema (AAE) is a rare disorder characterized by recurrent episodes of swelling (angioedema) in the skin and mucous membranes. Unlike hereditary angioedema (HAE), AAE typically develops in adulthood, often after age 40 or 50, and is not inherited. It results from an acquired deficiency or dysfunction of the C1 esterase inhibitor (C1-INH), a protein essential for regulating the complement system and controlling inflammation.

What Causes AAE?

AAE is caused by excessive activity of bradykinin, a molecule that increases blood vessel permeability and causes swelling. In a healthy immune system, C1-INH controls bradykinin production. In AAE, this regulatory function fails due to very low C1-INH activity.

There are two main subtypes of AAE:

Type I AAE occurs when C1-INH is consumed at an abnormally high rate. This is often associated with lymphoproliferative disorders (such as lymphoma or chronic lymphocytic leukemia), autoimmune diseases, or certain solid tumors.
Type II AAE is caused by autoantibodies that bind to and inactivate C1-INH, preventing it from functioning properly.

In both forms, low C1-INH activity leads to uncontrolled bradykinin buildup and swelling.

Associated Conditions

AAE is often linked to underlying conditions, particularly:

Lymphoproliferative disorders (e.g., non-Hodgkin lymphoma, CLL)
Autoimmune diseases (e.g., systemic lupus erythematosus)
Solid tumors (e.g., breast, renal, or stomach cancer)

In some cases, AAE may be the first sign of an undiagnosed illness.

Symptoms

AAE presents as unpredictable, non-itchy swelling that can affect:

The face, lips, tongue, or throat (potentially obstructing the airway)
The arms, hands, legs, or feet
The digestive tract, leading to abdominal pain, nausea, vomiting, or diarrhea
The genitals

Swelling episodes usually last 2 to 5 days and do not respond to antihistamines, corticosteroids, or epinephrine. Triggers may include trauma, infection, dental procedures, emotional stress, or may be unknown.

Diagnosis

AAE should be considered in adults who experience unexplained recurrent angioedema, especially in the absence of a family history of HAE. Diagnostic evaluation includes:

Measurement of C1-INH antigen levels (to assess quantity)
Measurement of C1-INH functional activity (to assess function)
Complement C4 level (often low)
Complement C1q level (typically low in AAE but normal in HAE)
Testing for anti-C1-INH autoantibodies (in suspected Type II AAE)
Genetic testing to exclude hereditary angioedema

Treatment

Treatment focuses on managing acute attacks, preventing future episodes, and addressing any underlying conditions.

Acute attack management:

C1-INH replacement therapies (e.g., Berinert, Cinryze)
Icatibant (a bradykinin receptor antagonist)
Ecallantide (a kallikrein inhibitor)
Fresh frozen plasma (used when specific therapies are unavailable)

Preventive treatment:

Antifibrinolytics (e.g., tranexamic acid, aminocaproic acid)
Attenuated androgens (used with caution due to side effects)

Long-term management:

Treating the underlying condition, such as a malignancy or autoimmune disease, may reduce or resolve angioedema episodes.

Key Differences Between AAE and HAE

Feature	AAE	HAE
Age of Onset	Typically after age 40–50	Usually during childhood or adolescence
Inheritance	Not inherited	Autosomal dominant
C1q Levels	Often low	Typically normal
Cause	Acquired C1-INH deficiency or dysfunction	Genetic mutation in C1-INH gene
Associated Conditions	Commonly linked to lymphoproliferative or autoimmune diseases	Usually occurs without other underlying illnesses

Summary

Acquired Angioedema (AAE) is a non-hereditary form of angioedema caused by an acquired deficiency or inactivation of the C1 esterase inhibitor protein. It most often affects adults later in life and is commonly associated with underlying illnesses such as lymphoproliferative or autoimmune disorders. AAE requires specialized testing and treatment distinct from allergy-related angioedema. Early recognition and treatment of the underlying condition can improve outcomes and reduce the frequency of attacks.

Acquired angioedema (AAE)